Last reviewed · How we verify
Incretin-based therapy
Incretin-based therapy enhances insulin secretion by mimicking or prolonging the action of incretin hormones (GLP-1 and GIP) that are released in response to oral glucose intake.
Incretin-based therapy enhances insulin secretion by mimicking or prolonging the action of incretin hormones (GLP-1 and GIP) that are released in response to oral glucose intake. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Incretin-based therapy |
|---|---|
| Also known as | Glucagon-like Peptide-1 Receptor Agonist |
| Sponsor | Nagaoka Red Cross Hospital |
| Drug class | Incretin mimetic or DPP-4 inhibitor |
| Target | GLP-1 receptor or DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Incretin hormones account for 50–70% of the postprandial insulin secretion in healthy individuals. Incretin-based therapies work by either mimicking GLP-1 receptor agonists (GLP-1 RAs) or inhibiting dipeptidyl peptidase-4 (DPP-4) to prevent degradation of endogenous incretins. Both approaches increase glucose-dependent insulin secretion and suppress glucagon, thereby lowering blood glucose levels in a glucose-dependent manner.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
- Headache
Key clinical trials
- The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
- Incretin-based Therapies, Nutrition, and Physical Activity (NA)
- Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease (PHASE4)
- A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar (PHASE2, PHASE3)
- Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy (PHASE4)
- Fibrosis Lessens After Metabolic Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Incretin-based therapy CI brief — competitive landscape report
- Incretin-based therapy updates RSS · CI watch RSS
- Nagaoka Red Cross Hospital portfolio CI